Stockhead’s Ashtyn Hiron sits down with Dimerix (ASX:DXB) CEO and managing director Nina Webster to close the books on 2023 and gain a sneak peek into what’s around the corner.

Dimerix works on pharmaceutical products to treat patients with rare inflammatory diseases including kidney and respiratory disease.

In 2023 the company inked an exclusive licence agreement with multinational pharmaceutical company Advanz Pharma covering the European Economic Area, UK, Switzerland, Canada, Australia, and New Zealand for commercialisation of its lead asset, DMX-200.

Tune in to hear what’s coming up for Dimerix in 2024.

Read MoreBiotech

Featured Companies

You might be interested in